Mayo Clinic Laboratory and Pathology Research Roundup: Oct. 17

The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.


Featured Abstract

The Prognostic Value of Multiparametric Flow Cytometry in AL Amyloidosis at Diagnosis and at the End of First-Line Treatment

amyloidMultiparametric flow cytometry (MFC) in AL amyloidosis has not been widely adopted and consequently there is little information on its clinical relevance. Mayo Clinic researchers studied 173 AL amyloidosis patients who underwent MFC immunophenotyping of bone marrow sample at diagnosis and 82 patients at the end of the first line of treatment (EOT). Based on the study results, researchers found that MFC is prognostic for AL amyloidosis at diagnosis and at the end of treatment. MFC may also have a role in the definition of hematological response. The study was published in Blood


Published to PubMed This Week

brentwestra

Brent Westra

Brent Westra is a Marketing Segment Manager at Mayo Medical Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.